Jaguar Health (JAGX) Net Equity Issued and Repurchased (2014 - 2025)

Jaguar Health (JAGX) has reported Net Equity Issued and Repurchased for 10 consecutive years, with $3.1 million the latest figure, recorded in Q3 2025.

• In Q3 2025, Net Equity Issued and Repurchased fell 88.85% year-over-year to $3.1 million; the TTM figure through Dec 2025 stood at $7.7 million (down 75.0% YoY), while the FY2025 annual figure was $2.4 million, down 92.28% from the prior year.
• Net Equity Issued and Repurchased climbed to $3.1 million in Q3 2025 per JAGX's latest filing, from $1.5 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $27.8 million in Q3 2024 and bottomed at -$11.6 million in Q3 2022.
• Historically, Net Equity Issued and Repurchased has averaged $3.7 million across 4 years, with a median of $3.0 million in 2024.
• Annual changes were most pronounced in 2022 — Net Equity Issued and Repurchased soared 347.39% — and 2025, when it tumbled 88.85%.
• Jaguar Health's Net Equity Issued and Repurchased stood at $2.0 million in 2021, then plunged by 670.3% to -$11.6 million in 2022, then surged by 125.86% to $3.0 million in 2024, then advanced by 3.33% to $3.1 million in 2025.
• Business Quant data shows JAGX's Net Equity Issued and Repurchased at $3.1 million in Q3 2025, $1.5 million in Q2 2025, and $3.1 million in Q1 2025.